Clinical trials: BOS
Graft Versus Host Disease (GVHD), Acute Myocardial Infarction (AMI)
University of Wisconsin hMSC Cell Bank: Bone Marrow Donor Protocol
The objective of this protocol is to use established standard criteria and methods for the collection of hMSC (human mesenchymal stromal cells) from healthy bone marrow donors.
- Trial name
- NCT01463475
- Testing
- Bone marrow aspirate
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Bronchiolitis Obliterans, Lung Transplant Rejection
Transplant Optimization Using Functional Imaging
The objective of this study is to detect Bronchiolitis Obliterans Syndrome (BOS) in an early stage using the outcome parameters generated by Functional Respiratory Imaging (FRI).
- Trial name
- TROFI (NCT02364674)
- Testing
- High Resolution Computed Tomography scan
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- FLUIDDA nv
Bronchiolitis Obliterans
L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients
Immunosuppression is a key intervention in patients with solid organ transplant and is usually achieved by combination therapy with systemic CsA or tacrolimus with azathioprine, mycophenolate mofetil (MMF), or corticoids.
- Trial name
- NCT01334892
- Testing
- Cyclosporine Inhalation Solution
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- Pari Pharma GmbH
Bronchiolitis Obliterans Syndrome
Imaging and Understanding BOS in Lung Transplantation
This study is a prospective, non-randomized, longitudinal, observational study that will recruit about 5 lung transplant patients per year for 3 years.
- Trial name
- NCT02316392
- Testing
- Hyperpolarized Helium-3 MRI
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Bronchiolitis Obliterans Syndrome, Chronic Lung Allograft Dysfunction
LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
The goal of this clinical trial is to learn about the safety and effectiveness of LAM-001 in patients who have developed bronchiolitis obliterans syndrome (BOS), a form of chronic rejection, after lung transplantation.
- Conditions
- Bronchiolitis Obliterans Syndrome, Chronic Lung Allograft Dysfunction, Lung Transplantation
- Trial name
- INSPO-BOS (NCT06018766)
- Testing
- LAM-001
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Steven Hays, MD
Bronchiolitis Obliterans Syndrome (BOS), Bronchiolitis Obliterans (BO)
Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation
This study investigates the safety and tolerability of Nintedanib in patients with bronchiolitis obliterans syndrome (BOS) following allogeneic hematopoietic cell transplantation.
- Trial name
- NINBOST2018 (NCT03805477)
- Testing
- Nintedanib
- Where
- 3 sites in Saudi Arabia, Switzerland
- Volunteers
- 20 people
- Sponsor
- University Hospital, Basel, Switzerland
Bronchiolitis Obliterans, Obliterative Bronchiolitis
Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)
The objective of the trial is to assess the long-term safety and efficacy of L-CsA plus Standard of Care (SoC) in the treatment of BOS in single (SLT) and double lung transplant (DLT) recipients.
- Conditions
- Bronchiolitis Obliterans, Obliterative Bronchiolitis, Bronchiolitis Obliterans Syndrome
- Trial name
- BOSTON-3 (NCT04039347)
- Testing
- Liposomal Cyclosporine A 5 mg, Liposomal Cyclosporine A 10 mg
- Where
- 37 sites in United States, Austria and 7 more
- Volunteers
- 164 people
- Sponsor
- Zambon SpA
Asthma, COPD
Evaluation of 3D Magnetic Resonance Spirometry: Comparison with Spirometry in Healthy Subjects and Patients with Respiratory Pathologies (asthma, COPD, Bilateral Lung Transplant)
Spirometry is now the gold standard technique for assessing lung function in humans. From the shape of a flow-volume curve measured while the patient, trained by the practitioner, performs forced breaths, the forced vital…
- Conditions
- Asthma, COPD, BOS
- Trial name
- gb-Spiro3D (NCT05724745)
- Testing
- 1. Standard spirometry, 2. 3D dynamic lung MRI at UTE in prone and supine positions, 3. Reversibility test with salbutamol
- Where
- France
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Commissariat A L'energie Atomique
Bronchiolitis Obliterans
Hp129 Xenon Imaging and BOS in Lung Transplantation
The research is being conducted to develop new imaging methods that are sufficiently sensitive to allow for early diagnosis of BOS, a chronic allograft rejection affecting 50-60% of lung transplanted recipients who survive 5…
- Trial name
- NCT03603899
- Testing
- Hp 129Xenon
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Bronchiolitis Obliterans
Extracorporeal Photopheresis in Patients With Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation
Investigation of photopheresis as new therapy regimen in patients with bronchiolitis obliterans syndrome after lung transplantation in a controlled, randomized study
- Trial name
- NCT00502554
- Testing
- photopheresis
- Where
- 2 sites in Germany
- Volunteers
- 12 people
- Sponsor
- Hannover Medical School
Lung Transplant Rejection
Macitentan in the Treatment of Organ Rejection After Lung Transplantation
Potential therapy with MACITENTAN in the treatment of Chronic Lung Allograft Dysfunction (CLAD) after Lung Transplantation. Pilot Study, Double-blind, "ADD-ON Therapy" with MACITENTAN to "usual standard of care immunosuppressive…
- Trial name
- NCT02893176
- Testing
- macitentan
- Where
- United States
- Sponsor
- University of California, Los Angeles
Lung Transplant, Bronchiolitis Obliterans
Viral Triggers in Pediatric Lung Transplantation
The purpose of this study is to determine whether respiratory viral infections increase the risk of bronchiolitis obliterans syndrome (BOS), obliterative bronchiolitis (OB), death, or retransplantation in children who have…
- Conditions
- Lung Transplant, Bronchiolitis Obliterans, Obliterative Bronchiolitis
- Trial name
- NCT00891865
- Where
- 6 sites in United States
- Volunteers
- 61 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Disorder Related to Lung Transplantation, Chronic Rejection of Lung Transplant
Standard Therapy Using Tacrolimus, Mycophenolate Mofetil and Prednisone For Chronic Lung Transplant Rejection (BOS)
This is a prospective single-center, open-label, randomized, controlled pilot study in the treatment of chronic rejection (CR), defined as grade 1 and 2 BOS, in adult recipients of a pulmonary allograft (single or double…
- Conditions
- Disorder Related to Lung Transplantation, Chronic Rejection of Lung Transplant, Decreased Immunologic Activity
- Trial name
- NCT04415476
- Testing
- Assigned Interventions
- Sponsor
- University of Maryland, Baltimore
Lung Transplantation, Bronchiolitis Obliterans Syndrome
Characterization of Bronchiolitis-obliterans Syndrome (BOS) Following Lung Transplantation
Chronic organ dysfunction after lung transplantation (BOS) is the most common cause of death in long-term survivors after lung transplantation and refractory to most interventions.
- Trial name
- NCT00774449
- Where
- Germany
- Volunteers
- 261 people
- Sponsor
- Hannover Medical School
Bronchiolitis Obliterans
Hyperpolarized 129Xe MRI for the Assessment of BOS With Late Onset LONIPC
The development of bronchiolitis obliterans syndrome (BOS) and other late onset non-infectious pulmonary complications (LONIPCs) following hematopoietic stem cell transplantation (HSCT) is associated with a significantly worse…
- Trial name
- BOS-MRI (NCT04029636)
- Testing
- Inhaled Hyperpolarized Xenon-129
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- Hamilton Health Sciences Corporation
Bronchiolitis Obliterans, Lung Transplant Rejection
Transplant Optimization Using Functional Imaging (TROFI)
The objective of this study is to detect Bronchiolitis Obliterans Syndrome (BOS) in an early stage using the outcome parameters generated by Functional Respiratory Imaging (FRI).
- Trial name
- TROFI_BE (NCT02441413)
- Testing
- High Resolution Computed Tomography scans
- Where
- Belgium
- Volunteers
- 3 people
- Sponsor
- FLUIDDA nv
Pre-Bronchiolitis Obliterans Syndrome
Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant
The goal of this Phase 3 clinical trial is to compare ARINA-1 (a nebulized immunomodulatory agent) plus Standard of Care vs Standard of Care alone.
- Trial name
- NCT05654922
- Testing
- ARINA-1, Standard of care only
- Where
- 22 sites in United States
- Volunteers
- 100 people
- Sponsor
- Renovion, Inc.
Lung-transplant Recipients
Nintedanib in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome Grade 0p-1-2
Lung transplantation (TxP) is now a validated treatment of end-stage pulmonary diseases, but long-term graft and patient survival are still hampered by the development of chronic allograft dysfunction (CLAD) affecting > 50% of…
- Trial name
- INFINITx BOS (NCT03283007)
- Testing
- Nintedanib
- Where
- France
- Volunteers
- 58 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Bronchiolitis Obliterans, Lung Transplant Rejection
Prospective Study for Transplant Optimization Using Functional Imaging (TROFI)
The objective of this study is to detect BOS in an early stage by using the outcome parameters generated by Functional Respiratory Imaging (FRI).
- Trial name
- NCT02488304
- Testing
- HRCT scans
- Where
- Belgium
- Volunteers
- 10 people
- Sponsor
- FLUIDDA nv
Bronchiolitis Obliterans
Long-term Safety Follow-up Study in the Prevention of Bronchiolitis Obliterans Syndrome (BOS)
The purpose of this study is to evaluate long-term safety of L-CsA in prevention of bronchiolitis obliterans syndrome (BOS) following lung transplantation (LTx) in patients previously enrolled in phase II/III L-CsA clinical trial…
- Trial name
- NCT01439958
- Testing
- Inhalation
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- Pari Pharma GmbH